{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:17:48Z","timestamp":1761920268210,"version":"3.37.3"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T00:00:00Z","timestamp":1492041600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0174858","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T13:32:19Z","timestamp":1492090339000},"page":"e0174858","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2219-5593","authenticated-orcid":true,"given":"Julia","family":"Kr\u00e4mer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Gerd","family":"Tenberge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Gaissmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Ruck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Heesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,4,13]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"CH Polman","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"RA Rudick","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"PS Sorensen","year":"2012","journal-title":"Mult Scler"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2147\/PPA.S20791","article-title":"An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations","volume":"9","author":"B Kornek","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"DB Clifford","year":"2010","journal-title":"Lancet Neurol"},{"unstructured":"PML-Inzidenz bei Patienten unter Therapie mit Natalizumab (TYSABRI). Biogen. June 2016. Available from: www.tysabri.de\/de_de\/home\/dcsecure\/tysabri.html<\/ext-link>.","key":"ref6"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.tips.2015.09.006","article-title":"PML: The Dark Side of Immunotherapy in Multiple Sclerosis","volume":"36","author":"C Warnke","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"20","key":"ref8","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"G Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"ref9","first-page":"668","article-title":"Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab","volume":"5","author":"C Antoniol","year":"2014","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"ref10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jneuroim.2014.10.011","article-title":"Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy","volume":"277","author":"F Serana","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"N Schwab","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24345","article-title":"Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab","volume":"77","author":"LM Villar","year":"2015","journal-title":"Ann Neurol"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"C Warnke","year":"2015","journal-title":"Mult Scler"},{"issue":"10","key":"ref14","article-title":"Low Body Weight as a Potential Surrogate Risk Factor for Progressive Multifocal Leukoencephalopathy","volume":"82","author":"J Foley","year":"2014","journal-title":"Neurology"},{"issue":"16","key":"ref15","article-title":"Is Aging and Immunosenescence a Risk Factor For Dimethyl Fumarate Induced PML?","volume":"86","author":"J Foley","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/2040622313514790","article-title":"First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks","volume":"5","author":"JA Nicholas","year":"2014","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"T Plavina","year":"2014","journal-title":"Ann Neurol"},{"unstructured":"Paul-Ehrlich-Institut. Rote Hand Brief: Tysabri\u2014Natalizumab. 2016 Mar 11. Available from: www.pei.de\/DE\/arzneimittelsicherheit-vigilanz\/pharmakovigilanz\/rote-hand-briefe\/rote-hand-briefe-node.html<\/ext-link>","key":"ref18"},{"unstructured":"Koendgen H, Chang I, Sperling B, Bloomgren G, Haddock B, Richman S, et al. New algorithm to estimate risk of natalizumab-associated progressive multifocal leukoencephalopathy (PML) in anti-JCV antibody positive patients: analyses of clinical trial data to provide further temporal precision and inform clinical practice. ECTRIMS Online Library. Koendgen H. 2016 Sep 16; 145932. Available from: http:\/\/onlinelibrary.ectrims-congress.eu\/ectrims\/2016\/32nd\/145932\/harold.koendgen.new.algorithm.to.estimate.risk.of.natalizumab-associated.html<\/ext-link>","key":"ref19"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","article-title":"Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?","volume":"20","author":"GR Cutter","year":"2014","journal-title":"Mult Scler"},{"unstructured":"Gold R, Hanschke S, Hemmer B, Wiendl H. Diagnose und Therapie der Multiplen Sklerose. Leitlinien der DGN. 2014 Apr. Available from: http:\/\/www.dgn.org\/leitlinien\/2333-ll-31-2012-diagnose-und-therapie-der-multiplen-sklerose<\/ext-link>","key":"ref21"},{"unstructured":"Fachinformation Tysabri. Available from: http:\/\/www.ema.europa.eu\/docs\/de_DE\/document_library\/EPAR_-_Product_Information\/human\/000603\/WC500044686.pdf<\/ext-link>","key":"ref22"},{"issue":"3","key":"ref23","first-page":"1","article-title":"Learning Bayesian Networks with the bnlearn R Package","volume":"35","author":"S Marco","year":"2010","journal-title":"Journal of Statistical Software"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/WCO.0b013e328360279f","article-title":"Progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"26","author":"KJ Baldwin","year":"2013","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/1352458512439238","article-title":"Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision","volume":"18","author":"C Tur","year":"2012","journal-title":"Mult Scler"},{"issue":"12","key":"ref26","article-title":"Risk acceptance in multiple sclerosis patients on natalizumab treatment","volume":"8","author":"C Tur","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"ref27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40263-014-0168-0","article-title":"Natalizumab: risk stratification of individual patients with multiple sclerosis","volume":"28","author":"C Tur","year":"2014","journal-title":"CNS Drugs"},{"issue":"Suppl 2","key":"ref28","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3949\/ccjm.78.s2.05","article-title":"Multiple sclerosis, natalizumab, and PML: helping patients decide","volume":"78","author":"RA Rudick","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2147\/TCRM.S41552","article-title":"Bridging, switching or drug holidays\u2014how to treat a patient who stops natalizumab?","volume":"9","author":"J Havla","year":"2013","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"ref30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","article-title":"Natalizumab dosage suspension: are we helping or hurting","volume":"68","author":"TW West","year":"2010","journal-title":"Ann Neurol"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1177\/1352458510379819","article-title":"Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists","volume":"16","author":"C Heesen","year":"2010","journal-title":"Mult Scler"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.msard.2015.03.003","article-title":"Risk tolerance to MS therapies: Survey results from the NARCOMS registry","volume":"4","author":"RJ Fox","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"C Warnke","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"N Schwab","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"L Gorelik","year":"2010","journal-title":"Ann Neurol"},{"issue":"22","key":"ref36","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0b013e3182583022","article-title":"Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort","volume":"78","author":"AK Trampe","year":"2012","journal-title":"Neurology"},{"issue":"7","key":"ref37","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"O Outteryck","year":"2014","journal-title":"Mult Scler"},{"unstructured":"Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri. European Medicines Agency (EMA). 2016 Feb 12. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2016\/02\/news_detail_002471.jsp&mid=WC0b01ac058004d5c1<\/ext-link>.","key":"ref38"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0174858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:16:15Z","timestamp":1540340175000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0174858"}},"subtitle":[],"editor":[{"given":"Christoph","family":"Kleinschnitz","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,13]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0174858","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2017,4,13]]}}}